March 2021

Contents

Editorial

• HTB: no. 3 – plus HIV and COVID-19 (12 March 2021)

In memory

• In memory: Dr Charles Boucher – leading HIV doctor, researcher and educator

Conference reports

• 28th Conference on Retroviruses and Opportunistic Infections (CROI 2021)

• CROI 2021: Urgency of global access to vaccines, the potential of mAbs and the lessons learned from HIV

• CROI 2021: Community challenge 6-month CROI pay wall – rather than usual open access…

• CROI 2021: Once-daily GSK254 maturation inhibitor as treatment for HIV multidrug resistance

• CROI 2021: Dosing for once-weekly oral ART: islatravir plus MK-8507 studies due to start in 2021

• CROI 2021: Islatravir dosing for once-monthly and annual PrEP: if effective this could end HIV transmission

• CROI 2021: Dolutegravir with recycled tenofovir and lamivudine performs well second-line: primary results from the NADIA trial

• CROI 2021: HIV capsid uncoats in the CD4 nucleus rather than the cytoplasm – viral lifecycle updated…

• CROI 2021: Community HIV cure workshops online

Side effects

• Chronic kidney disease (CKD) in HIV positive people linked to time with low CD4 count: partly reversible after effective ART

Research studies

• Switch study for people with insomnia using dolutegravir

COVID-19: vaccine research

• Janssen/J&J vaccine against COVID-19 is approved in the EU

COVID-19: investigational drugs

• Baricitinib improves recovery in sub-group of adults hospitalised COVID-19: results from ACTT-2 study

• Ivermectin has no impact in treating mild COVID-19 in 400 adults in Columbia

• No benefit from BRII and GSK monoclonal antibodies against COVID-19 in ACTIV-3 study

PDFs

• HTB: no.3 – plus HIV and COVID-19 (12 March 2021)